The Executive Management and the Board of Directors gather professionals of the pharmaceutical and biotech industry as well as finance.
Chairman of the Board
Ir. Agronomy, MBA, Thierry Legon was in charge for ten years of the management of the intellectual property and technology transfer of the University of Brussels (ULB). Thierry was also a board member of Euroscreen (a drug discovery biotech company) for eight years.
In May 1997, Thierry founded ASIT biotech as a spin-off company of the ULB. As Chief Executive Officer (CEO) since 2000, Thierry has successfully designed consecutive business plans, raised the required funds and is leading the team to achieve the goals of the company.
M.D. PhD, graduated in Internal Medicine and Clinical Biology, Honorary Professor of Mucosal Immunology at Université Libre de Bruxelles, Head Department of Clinical Biology at CHU-Brugmann and Hôpital Universitaire des Enfants - Reine Fabiola (ULB) Professor Duchateau is one of the inventor of the first patents on tolerance induction to allergy and graft rejection, new LED tests, owned by ASIT biotech. Professor Duchateau was cofounder of ASIT biotech and he is now Honorary President.
As managing Partner of Oukelos, François is working as independent consultant in pharmaceutical product strategic marketing. He spent more than twenty-five years in the biopharmaceutical industry, both in Europe and the United States, and holding both operational and higher management functions like Director of Global Marketing for Prozac® at Eli Lilly, Senior Director of Asia-Pacific Marketing at Merck & Co. and Vice-President of Global Marketing at UCB. François graduated from Reims Management School, received a master degree in International Relations from University of Paris-Sorbonne and holds an MBA from the Stern School of Business, New York University.
Everard van der Straten
Everard van der Straten holds a master from Solvay Business School. After a short career as auditor at Arthur and Anderson & Co, Everard was managing director of Metallo-Chimique Group and afterwards Board Member of the Metallum Group until end 2008. Currently, Everard is as well Business Angel.
Master in Management Economics, Marc Foidart manages Cide-Socran since its creation. As CEO of Spinventure fund and vice director of Meusinvest, Marc has a deep knowledge in funding and a 15 years of expertise of Biotech companies and technological start-up.
Henri De Meyer
Henri DE MEYER holds two Master Degrees, both from Solvay Business School (in Management and Taxation Management) and a post grade from Université Libre de Bruxelles (in Human Resources Management). He has been working for 18 years in the Venture Capital Sector as Investment Manager and, since 2000, as Crisis Manager in charge of restructuring companies and M&A assignments.
Yves Désiront is the Managing Partner of a private equity fund based in Luxembourg and is acting, since October 2014, as Group CFO under a consulting contract with BGP Investment, a Luxembourg real estate group based in Luxembourg. Previously he acted as Group CFO of Orco Property Group. Prior to this he served in various roles at Groupe Bruxelles Lambert and Générale de Banque. Yves Désiront obtained in 1994 a master degree as Ingénieur Commercial in Business Administration and Technology Interface from I.C.H.E.C. Brussels.